A randomized, Phase IIb study investigating oliceridine (TRV130), a novel µ-receptor G-protein pathway selective (µ-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty

A randomized, Phase IIb study investigating oliceridine (TRV130), a novel µ-receptor G-protein pathway selective (µ-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty

Neil Singla,1 Harold S Minkowitz,2 David G Soergel,3 David A Burt,3 Ruth Ann Subach,3 Monica Y Salamea,3 Michael J Fossler,3 Franck Skobieranda3 1Lotus Clinical Research, Pasadena, CA, 2Memorial Hermann Memorial City Medical Center, Houston, TX, 3Trevena, Inc, King of Prussia, PA, USA Background: Ol...

Full description

Bibliographic Details
Main Authors: Singla N, Minkowitz HS, Soergel DG, Burt DA, Subach RA, Salamea MY, Fossler MJ, Skobieranda F
Format: Article
Language:English
Published: Dove Medical Press 2017-10-01
Series:Journal of Pain Research
Subjects:
TRV130
acute pain
analgesic
opioid
biased ligand
Online Access:https://www.dovepress.com/a-randomized--phase-iib-study-investigating-oliceridine-trv130-a-novel-peer-reviewed-article-JPR

Internet

https://www.dovepress.com/a-randomized--phase-iib-study-investigating-oliceridine-trv130-a-novel-peer-reviewed-article-JPR

Similar Items